Role of immunological markers in the characterisation of lymphoproliferative disorders The value of immunological marker studies as a diagnostic tool in chronic lymphoproliferative disorders can be summarised as follows:
(1) Markers are essential to distinguish: (A) immature/acute lymphoblastic leukaemias (ALL), which, with the exception of Burkitt's or L3-ALL, are as a rule terminal deoxynucleotidyl transferase (TdT) positive, from mature/chronic lymphoproliferative disorders which are TdT negative. This is important when the clinical and cytological features of a chronic lymphoproliferative disorder resemble those of acute leukaemia, as may be the case of large cell lymphomas in leukaemic phase.3 (B) B cell from T cell lymphoid neoplasms.
(2) Immunophenotyping permits the establishment of clonality in B cell malignancies and the distinction from non-neoplastic reactive lymphocytosis. This is achieved by demonstrating the expression of only one of the two types of the immunoglobulin (Ig) light chain (K or A) on the surface or in the cytoplasm of the lymphocytes. By contrast, in reactive conditions, both K and A positive B cells will be present.
There is no immunological marker to demonstrate clonality in T cells; however, aberrant phenotypes which are not present or are very uncommon among normal T cells, are suggestive of a clonal T cell proliferation.4 (3) Markers are useful to confirm or establish the diagnosis of a particular disease entity. Despite the lack of specificity of markers for the different lymphoid disorders, there are some well defined phenotypes such as that of B cell chronic lymphocytic leukaemia (B-CLL) and hairy cell leukaemia5 which are of great value for the recognition of these diseases, particularly when other clinical and laboratory features are atypical. The same procedure is applied for flow cytometry but the cell pellet instead of being resuspended in glycerol/PBS, is resuspended in 500 ,ul of Isoton and assessed on the flow cytometer. If analysis of the sample is performed more than four hours after staining the cell pellet should be fixed in 1% paraformaldehyde in 0-85% saline instead of being resuspended in Isoton.
Recommendations
Whole blood can also be tested by flow cytometry, except for the detection of SmIg. The manufacturer's instructions for the lysing procedure should be followed. Usually, In general terms, the use of the indirect immunofluorescence as the routine method is recommended for the following reasons: (A) the direct technique is less sensitive for the detection of an antigen when the expression in the membrane is weak; (B) some monoclonal antibodies are not commercially available as reagents directly conjugated to fluorochromes; and, (C) the indirect method is less expensive. The direct immunofluorescence method is recommended when double immunolabelling is performed.
Negative control preparations are always set up by replacing the monoclonal antibody with a mouse immunoglobulin of the same isotype and, when possible, positive controls are carried out on normal or leukaemic samples. For practical purposes, a mixture of mouse immunoglobulin of the various isotypes can be used as a negative control. The methodology for the detection of immunoglobulin (heavy and light chains) in the cell membrane is similar to that described above, with slight modifications. Before the immunological reaction, the isolated cells are resuspended in tissue culture medium and incubated at 37°C for 30 to 60 minutes to remove extrinsic immunoglobulin bound by the Fcy receptors present on B cells. Following this, the cells are washed once in PBS with 0-2% BSA and are subsequently stained with the anti-immunoglobulin reagents following standard techniques except that the buffer used for all washes does not contain 2% human AB serum. Fast Red TR salt, rinsed in distilled water and counterstained with Harris's haematoxylin for 10 to 20 seconds. The slides, still wet, are mounted with Glycergel (Dako) and assessed under an ordinary microscope. Cells positive with a monoclonal antibody will be seen with red stain in the cytoplasm or on the cell surface.
Negative controls are set up by replacing the monoclonal antibody with a mouse immunoglobulin of the same isotype and normal blood and bone marrow smears are used as positive control when required.
Interpretation of results
Results have to be considered in the context of the cell morphology, and the proportion of leukaemic cells has to be estimated in the samples analysed. Therefore, the cutoff point to consider a marker positive will vary. For instance, for samples from primary leukaemias such as B-CLL or prolymphocytic leukaemia (PLL), which usually contain over 80% leukaemic cells, a cutoff point of 30% of cells stained with a marker can be considered to be positive. By contrast, in diseases such as non-Hodgkin's lymphomas in leukaemic phase or hairy cell leukaemia, the proportion of malignant cells ranges from a minority to large numbers. Therefore, results must be interpreted in each case and for each particular marker, according to whether the marker is or is not expressed in normal blood lymphocytes. For instance, 10% of cells positive with B-ly-7, which is consistently negative in normal lymphocytes, can be considered a positive finding; the interpretation will be different with the marker CD2 which is positive in most normal blood T lymphocytes.
The lack of specificity of most of the markers also needs to be considered and results must be interpreted taking into consideration findings with the whole panel of markers investigated and not of a marker in isolation. In the cases with a T cell phenotype (CD2 +, CD5 +/-), the use of the following monoclonal antibody is recommended2 4: In the cases in which the first panel shows a clonal B cell disorder with a phenotype atypical for B-CLL, the second panel of markers to be used needs to be tailored according to the diagnosis suspected from clinical features and cell morphology. For instance, if a diagnosis of hairy cell leukaemia is entertained, the monoclonal antibody panel B-ly-7, CD25, CD1 ic and HC2 will be useful to confirm the diagnosis and distinguish hairy cell leukaemia from other B cell conditions, such as the hairy cell leukaemia variant,59 10 or splenic lymphoma with villous lymphocytes"I with which it may be confused.
Optional markers which sometimes give relevant information are CD10 when a diagnosis of follicular lymphoma in leukaemic phase is suspected'2 and CD38 in cases in which lymphoplasmacytic differentiation or plasma cell leukaemia is suspected from morphological examination.
A situation which may arise is that in which all the markers tested in the first panel are negative. The diagnosis of plasma cell leukaemia should then be suspected and tests on fixed cells to detect cytoplasmic immunoglobulin light chains and tests with CD38 should be carried out."3
The most characteristic immunophenotypic profiles on the various chronic B and T lymphoproliferative disorders are shown in tables 1 and 2.
Indications for immunophenotyping Immunophenotypic analysis is indicated on blood or bone marrow samples from all chronic lymphoproliferative disorders, including:
(A) primary lymphoid leukaemias; (B) leukaemia or lymphoma syndromes, or non-Hodgkin's lymphoma in leukaemic phase when there are at least 10% circulating abnormal cells; (C) non-Hodgkin's lymphoma with bone marrow infiltration.
